중합효소 연쇄 반응 시장 보고서 : 제품, 최종사용자, 지역별(2024-2032년)

The global polymerase chain reaction market size reached US$ 7.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 13.9 Billion by 2032, exhibiting a growth rate (CAGR) of 6.5% during 2024-2032.

Polymerase chain reaction (PCR) refers to a molecular diagnostic technique that is used to make multiple copies of a segment of DNA. A PCR machine is used to manipulate the temperature of the sample in an automatic and pre-programmed procedure to generate millions of copies of DNA sequencing accurately. This technology identifies and cultures disease-causing microorganisms, which aid in the detection of tuberculosis, Acquired Immunodeficiency Syndrome (AIDS), infections and Lyme disease. Owing to this, it finds extensive applications across various life science-related fields, such as genetics, biotechnology, molecular biology, drug discovery and clinical diagnostics.

Global Polymerase Chain Reaction Market Trends and Drivers:

The increasing prevalence of various infectious diseases and genetic disorders is one of the key factors driving the growth of the market. The rising geriatric population across the globe, which is more prone to chronic medical ailments, is also driving the industry growth. The outbreak of the coronavirus disease (COVID-19) pandemic has further led to the widespread adoption of PCR technologies for accurate diagnosis and early detection of infections. PCR devices also aid in minimizing the risks of contamination and the chances of human errors in the entire process.

The increasing demand for personalized and precision medicines is also creating a positive outlook for the market. These medicines aim to provide tailor-made therapies, which are identified and developed using PCR technologies. Other factors, including the increasing application in clinical diagnostics, along with extensive research and development (R&D) activities in the field of biotechnology, are expected to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global polymerase chain reaction market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on product and end user.

Breakup by Product:

Instruments

Standard PCR Systems

Digital PCR Systems

Real-Time PCR Systems

Reagents and Consumables

Software and Services

Breakup by End User:

Academic and Research Institutes

Clinical Diagnostics Labs and Hospitals

Pharmaceutical and Biotechnology Companies

Others

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Agilent Technologies Inc., BD (Becton, Dickinson and Company), BioMerieux (Institut Merieux SA), Bio-RAD Laboratories Inc., F. Hoffmann-La Roche AG, Fluidigm Corporation, Merck KGaA, Perkinelmer Inc., Promega Corporation, Takara Bio Inc. and Thermo Fisher Scientific Inc.

Key Questions Answered in This Report:

• How has the global polymerase chain reaction market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global polymerase chain reaction market?
• What are the key regional markets?
• What is the breakup of the market based on the product?
• What is the breakup of the market based on the end user?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global polymerase chain reaction market and who are the key players?
• What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Polymerase Chain Reaction Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Instruments
  • 6.1.1 Market Trends
  • 6.1.2 Market Breakup by Type
    • 6.1.2.1 Standard PCR Systems
      • 6.1.2.1.1 Market Trends
      • 6.1.2.1.2 Market Forecast
    • 6.1.2.2 Digital PCR Systems
      • 6.1.2.2.1 Market Trends
      • 6.1.2.2.2 Market Forecast
    • 6.1.2.3 Real-Time PCR Systems
      • 6.1.2.3.1 Market Trends
      • 6.1.2.3.2 Market Forecast
  • 6.1.3 Market Forecast
• 6.2 Reagents and Consumables
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Software and Services
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by End User

• 7.1 Academic and Research Institutes
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Clinical Diagnostics Labs and Hospitals
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Pharmaceutical and Biotechnology Companies
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Others
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast

8 Market Breakup by Region

• 8.1 North America
  • 8.1.1 United States
    • 8.1.1.1 Market Trends
    • 8.1.1.2 Market Forecast
  • 8.1.2 Canada
    • 8.1.2.1 Market Trends
    • 8.1.2.2 Market Forecast
• 8.2 Asia Pacific
  • 8.2.1 China
    • 8.2.1.1 Market Trends
    • 8.2.1.2 Market Forecast
  • 8.2.2 Japan
    • 8.2.2.1 Market Trends
    • 8.2.2.2 Market Forecast
  • 8.2.3 India
    • 8.2.3.1 Market Trends
    • 8.2.3.2 Market Forecast
  • 8.2.4 South Korea
    • 8.2.4.1 Market Trends
    • 8.2.4.2 Market Forecast
  • 8.2.5 Australia
    • 8.2.5.1 Market Trends
    • 8.2.5.2 Market Forecast
  • 8.2.6 Indonesia
    • 8.2.6.1 Market Trends
    • 8.2.6.2 Market Forecast
  • 8.2.7 Others
    • 8.2.7.1 Market Trends
    • 8.2.7.2 Market Forecast
• 8.3 Europe
  • 8.3.1 Germany
    • 8.3.1.1 Market Trends
    • 8.3.1.2 Market Forecast
  • 8.3.2 France
    • 8.3.2.1 Market Trends
    • 8.3.2.2 Market Forecast
  • 8.3.3 United Kingdom
    • 8.3.3.1 Market Trends
    • 8.3.3.2 Market Forecast
  • 8.3.4 Italy
    • 8.3.4.1 Market Trends
    • 8.3.4.2 Market Forecast
  • 8.3.5 Spain
    • 8.3.5.1 Market Trends
    • 8.3.5.2 Market Forecast
  • 8.3.6 Russia
    • 8.3.6.1 Market Trends
    • 8.3.6.2 Market Forecast
  • 8.3.7 Others
    • 8.3.7.1 Market Trends
    • 8.3.7.2 Market Forecast
• 8.4 Latin America
  • 8.4.1 Brazil
    • 8.4.1.1 Market Trends
    • 8.4.1.2 Market Forecast
  • 8.4.2 Mexico
    • 8.4.2.1 Market Trends
    • 8.4.2.2 Market Forecast
  • 8.4.3 Others
    • 8.4.3.1 Market Trends
    • 8.4.3.2 Market Forecast
• 8.5 Middle East and Africa
  • 8.5.1 Market Trends
  • 8.5.2 Market Breakup by Country
  • 8.5.3 Market Forecast

9 SWOT Analysis

• 9.1 Overview
• 9.2 Strengths
• 9.3 Weaknesses
• 9.4 Opportunities
• 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

• 11.1 Overview
• 11.2 Bargaining Power of Buyers
• 11.3 Bargaining Power of Suppliers
• 11.4 Degree of Competition
• 11.5 Threat of New Entrants
• 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

• 13.1 Market Structure
• 13.2 Key Players
• 13.3 Profiles of Key Players
  • 13.3.1 Agilent Technologies Inc.
    • 13.3.1.1 Company Overview
    • 13.3.1.2 Product Portfolio
    • 13.3.1.3 Financials
    • 13.3.1.4 SWOT Analysis
  • 13.3.2 BD (Becton, Dickinson and Company)
    • 13.3.2.1 Company Overview
    • 13.3.2.2 Product Portfolio
    • 13.3.2.3 Financials
    • 13.3.2.4 SWOT Analysis
  • 13.3.3 BioMerieux (Institut Merieux SA)
    • 13.3.3.1 Company Overview
    • 13.3.3.2 Product Portfolio
    • 13.3.3.3 Financials
    • 13.3.3.4 SWOT Analysis
  • 13.3.4 Bio-RAD Laboratories Inc.
    • 13.3.4.1 Company Overview
    • 13.3.4.2 Product Portfolio
    • 13.3.4.3 Financials
    • 13.3.4.4 SWOT Analysis
  • 13.3.5 F. Hoffmann-La Roche AG
    • 13.3.5.1 Company Overview
    • 13.3.5.2 Product Portfolio
    • 13.3.5.3 Financials
  • 13.3.6 Fluidigm Corporation
    • 13.3.6.1 Company Overview
    • 13.3.6.2 Product Portfolio
    • 13.3.6.3 Financials
  • 13.3.7 Merck KGaA
    • 13.3.7.1 Company Overview
    • 13.3.7.2 Product Portfolio
    • 13.3.7.3 Financials
    • 13.3.7.4 SWOT Analysis
  • 13.3.8 Perkinelmer Inc.
    • 13.3.8.1 Company Overview
    • 13.3.8.2 Product Portfolio
    • 13.3.8.3 Financials
    • 13.3.8.4 SWOT Analysis
  • 13.3.9 Promega Corporation
    • 13.3.9.1 Company Overview
    • 13.3.9.2 Product Portfolio
  • 13.3.10 Takara Bio Inc.
    • 13.3.10.1 Company Overview
    • 13.3.10.2 Product Portfolio
    • 13.3.10.3 Financials
  • 13.3.11 Thermo Fisher Scientific Inc.
    • 13.3.11.1 Company Overview
    • 13.3.11.2 Product Portfolio
    • 13.3.11.3 Financials
    • 13.3.11.4 SWOT Analysis